A highly potent antibody effective against SARS-CoV-2 variants of concern.

Control of the ongoing SARS-CoV-2 pandemic is endangered by the emergence of viral variants with increased transmission efficiency, resistance to marketed therapeutic antibodies, and reduced sensitivity to vaccine-induced immunity. Here, we screen B cells from COVID-19 donors and identify P5C3, a highly potent and broadly neutralizing monoclonal antibody with picomolar ...
neutralizing activity against all SARS-CoV-2 variants of concern (VOCs) identified to date. Structural characterization of P5C3 Fab in complex with the spike demonstrates a neutralizing activity defined by a large buried surface area, highly overlapping with the receptor-binding domain (RBD) surface necessary for ACE2 interaction. We further demonstrate that P5C3 shows complete prophylactic protection in the SARS-CoV-2-infected hamster challenge model. These results indicate that P5C3 opens exciting perspectives either as a prophylactic agent in immunocompromised individuals with poor response to vaccination or as combination therapy in SARS-CoV-2-infected individuals.
Mesh Terms:
Animals, Antibodies, Neutralizing, Antibodies, Viral, B-Lymphocytes, Broadly Neutralizing Antibodies, COVID-19, COVID-19 Drug Treatment, Cell Line, Cricetinae, Disease Models, Animal, Epitopes, Humans, Immunoglobulin Fab Fragments, Neutralization Tests, Protein Binding, SARS-CoV-2, Spike Glycoprotein, Coronavirus, Structure-Activity Relationship, Vaccination
Cell Rep
Date: Oct. 12, 2021
Download Curated Data For This Publication
245689
Switch View:
  • Interactions 1